19725-81-6

Upstream product

• 1227253-51-1 5-chloro-2-(2-ethoxy-2-oxoethyl)benzoic acid 
• 22901-69-5 5-amino-2-(carboxymethyl)benzoic acid 
• 19722-72-6 (4-Chlor-2-methoxycarbonyl-phenyl)-diazomethyl-keton 
• 64481-29-4 2-methoxycarbonylmethyl-5-amino-benzoic acid methyl ester 
• 118-45-6 4-chlorophthalic anhydride 
• 22479-41-0 2-Amino-5-chlor-3-cyano-1H-inden 
• 22479-42-1 6-Chlor-1-cyano-2-indanon 
• 22479-38-5 4-chloro-1,2-bis-cyanomethyl-benzene 
• 31684-14-7 1,2-bis(bromomethyl)-4-chlorobenzene 
• 19725-80-5 4-chloro-2-methoxycarbonyl-phenyl acetic acid methyl ester 
• 22479-44-3 5-Chlor-3-cyano-2-methoxy-1H-inden 
• 3898-66-6 2-(carboxymethyl)-5-nitrobenzoic acid 

Relevant academic research and scientific papers

NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections by using the novel compounds, processes for preparation of the compounds, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with viruses belonging to the family of the Flaviviridae and more preferably infections with Hepatitis C virus (HCV). The present invention also relates to the novel compounds for use as a medicine, more preferably for use as a medicine for the prevention or treatment of viral infections, preferably infections with viruses belonging to the family of the Flaviviridae.

Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain

We report herein the synthesis of a series of 19 2-hydroxyisoquinoline-1, 3(2H,4H)-dione derivatives variously substituted at position 7 aimed at inhibiting selectively two-metal ion catalytic active sites. The compounds were tested against HIV-1 reverse